25 - 28 June 2014 Barcelona
1-PD | Cetuximab every 2 weeks with first-line chemotherapy in APEC study patients with metastatic colorectal cancer grouped according to EGFR expression | Lucy Kilpatrick | Received |
2-PD | KRAS/NRAS and BRAF mutations in the 20050181 study of panitumumab FOLFIRI for the 2nd-line treatment of metastatic colorectal cancer: Updated analysis | Marc Peeters | Received |
2-P | Detection of c-KIT and PDGFRa mutations in GIST by Next Generation Sequencing. | celine de rop | Received |
3-PD | Real-life use of cetuximab in 1st-line treatment of unresectable metastatic colorectal cancer (mCRC) and outcomes after surgical resection of metastases: Updated data from the EREBUS cohort | Denis Smith | Received |
4-PD | The PRIME study: Survival outcomes in patients with KRAS/NRAS wild-type metastatic colorectal cancer and non-liver-limited disease | Jean-Yves Douillard | Received |
5-PD | Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC) | Marta Schirripa | Received |
6-P | MicroRNA Expression Analysis in Gastric Cancer Using Clustering Method Based on Microarray Data | Sally Yepes | Received |
6-PD | Panitumumab plus FOLFOX4 or panitumumab plus FOLFIRI in subjects with wild-type KRAS (exon 2) colorectal cancer and multiple or unresectable liver-limited metastases: data from the randomized, phase II PLANET study | Montse Armengol | Received |
7-O | Subgroup analyses in RAS mutant, BRAF mutant and all wt metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study | Chiara Cremolini | Received |
9-O | Phase I study of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC) MLN0264 in adult patients with advanced gastrointestinal malignancies expressing GCC | Jason Faris | Received |
9-P | Real-world treatment patterns among patients with advanced gastric cancer in Taiwan | Christine Collins | Received |
10-O | AXE Beam: Neo-adjuvant triplet versus doublet therapy with radiation and total mesorectal excision for locally advanced rectal cancer a randomized phase II study at the end of recruitment | Gabriela Chiritescu | Received |
11-PD | Circulating tumor cells (CTCs) as prognostic biomarker in patients with advanced chemorefractory, RAS wild-type colorectal cancer (CRC) treated with cetuximab or panitumumab | Valeria Musella | Received |
12-O | Are the Benefits of Aspirin in Colorectal Cancer limited to PIK3CA Mutated Tumours? | Ruth Langley | Received |
13-PD | Endoscopic treatment of early esophageal carcinoma: a prospective evaluation of 47 consecutive cases with promising results in patients with T1b cancers | Jana Krajciova | Received |
13-O | Dietary fatty acids intake and colorectal cancer risk: the Rotterdam Study | Bledar Kraja | Received |
14-PD | Clinical advantages of laparoscopic colorectal cancer surgery for the high elderly patients over 85 years old | Mr Tomizawa | Received |
16-PD | TUMOR BUDDING IN COLORECTAL CANCER WITH REGARDS TO MISMATCH REPAIR STATUS PROGNOSTIC VALUE? | Mia Karlberg | Received |
17-P | LOCAL RECURRENCE RATE FOLLOWING TOTAL GASTRECTOMY BY TRANSABDOMINAL APPROACH FOR SIEWERTS TYPE II ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA | Ramiz Bayramov | Received |
18-P | Evaluation of patient characteristics and 5-years survival rate in patients operated for gastric cancer in Bulgaria | Kostadin Angelov | Received |
18-PD | An Indirect Treatment Comparison and Cost-effectiveness Analysis Comparing FOLFIRINOX with nab-Paclitaxel plus Gemcitabine for First-line Treatment for Patients with Metastatic Pancreatic Cancer | Sarah Hollmann | Received |
19-P | Primary gastric lymphomas: About 216 cases. | Ines Ben Safta | Received |
19-PD | ORGAN PRESERVATION USING CONTACT RADIOTHERAPY FOR EARLY RECTAL CANCER: OUTCOMES OF PATIENTS TREATED AT A SINGLE CENTRE IN THE UNITED KINGDOM | Amandeep Dhadda | Received |
21-PD | Value of KRAS, BRAF and PIK3CA Mutations and Benefits from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis | Yusuke Sasaki | Received |
22-P | Pharmacokinetics of sunitinib in patients with liver cirrhosis and hepatocellular carcinoma | Michele Basso | Received |
23-PD | Validation Study of a Blood-based Gene Expression Signature for Colorectal Cancer Detection | Qinghua XU | Received |
24-P | Upregulation of C4.4A in hepatocellular carcinoma | Magdalena Grtz | Received |
27-P | The genetic background of pancreatic cancer: Genes that might be biomarkers or indicators of metastasis to the lung | Panagiotis Apostolou | Received |
28-P | Subgroup analyses based on liver metastases and the number of metastatic sites from the MPACT phase III trial of nab-paclitaxel plus gemcitabine vs gemcitabine alone for metastatic pancreatic cancer | Michele Patton | Received |
29-P | nab-Paclitaxel plus gemcitabine vs gemcitabine alone for patients with metastatic pancreatic cancer: influence of primary pancreatic tumor location on efficacy and treatment exposure in the MPACT phase III trial | Michele Patton | Received |
32-P | Apoptosis and anergy of T cell induced by pancreatic stellate cells derived Galectin-1 in pancreatic cancer | Dong Tang | Received |
34-P | Folate intake and selected gastrointestinal cancers morbidity in Poland in the years 1960-2010 | Miroslaw Jarosz | Received |
36-P | Angiogenic markers of response to neoadjuvant therapy and long-term prognosis in locally advance rectal cancers - a critical analysis of available data | Olivia Lock | Received |
37-P | Malignant lymphoma diagnosed from gastrointestinal biopsy | Kazuhiko Natori | Received |
40-P | A Phase I dose-escalation and pharmacokinetic Study of S-1 plus nab-Paclitaxel in Patients with Unresectable or Recurrent Gastric Cancer | Kenji Ishido | Received |
42-P | Efficacy and safety of triweekly docetaxel, oxaliplatin, fluorouracil, and Folinic acid (DOFF) in patients with advanced gastric or gastroesophageal adenocarcinoma.(Poster presentation). | ABLAVI ADANI-IFE | Received |
44-P | Evaluation of docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy for resectable gastric and esophago-gastric cancer. | Marcelo Garrido | Received |
45-P | Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002) | Yutaka Kimura | Received |
46-P | Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy | Shigeyuki Tamura | Received |
47-P | Perioperative chemotherapy with folfox in resectable gastro-oesophageal adenocarcinoma: an AGEO multicentric retrospective study | Florence MARY | Received |
49-P | Immediate and long-term outcome of ESD for differentiated intramucosal gastric cancer compared to surgical resection | Sung Min Park | Received |
52-P | Gastric Cancer in Young Adults: Experience from Nepal | Bishnu Prasad Kandel | Received |
55-P | Perioperative chemotherapy of resectable gastroesophageal cancer in elderly patients: a retrospective analysis | Catarina Cardoso | Received |
56-P | Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced gastroesophageal cancer: A retrospective pooled analysis of individual patient data | Silvia Spoerl | Received |
57-P | Chemotherapy and target therapy of advanced stomach cancer. | Olga Kuznetsova | Received |
58-P | Single centre experience of palliative chemotherapy for upper gastrointestinal cancer | Victoria Plested | Received |
59-P | A single centre review of incidence of venous thromboembolism (VTE) in patients receiving palliative chemotherapy for upper gastrointestinal cancers and the impact on outcomes | Victoria Plested | Received |
60-P | Comparative study between using antracycline based and taxane based regimens as first line therapy for advanced and metastatic gastric cancer. | Abeer Ibrahim | Received |
66-P | Does biology and location predict chemotherapy benefit? Patients with distal gastric cancer have superior outcome with addition of taxanes into combination chemotherapy while proximal and diffuse gastric cancers dont. | ali murat sedef | Received |
67-P | Treatment Patterns and Outcomes of Patients with Gastric Cancer in the US: A retrospective analysis of electronic medical record (EMR) data | Lisa Hess | Received |
69-P | Costs and patterns of gastric cancer care in the US: A retrospective analysis of administrative claims data | Lisa Hess | Received |
71-P | Gastric cancer risk screening with combined assay for serum anti-Helicobacter pylori IgG antibody and pepsinogen level, so-called ABC method ; Can we need imaging study for gastric cancer screening ? | Takayuki Nakamura | Received |
73-P | COMPARISON OF THE AVERAGE BODY WEIGHT AND WAIST CIRCUMFERENCE IN PATIENT WITH BARRETTS OESOPHAGUS AND PATIENT WITHOUT LESIONS | Miros&322;aw Jarosz | Received |
79-P | The risk factors of postoperative external drainage after gastrectomy without prophylactic intra-peritoneal drainage for gastric cancer | Janghee Lee | Received |
80-P | Treatment outcome after D2 dissection in operable gastric cancer a retrospective analysis. | Shaikat Gupta | Received |
82-P | Results After D-2 Resection With Spleen And Distal Pancreas Preserved For Gastric Cancer Treatment | Antonio Chiappa | Received |
83-P | Devine gastric exclusion: for a better palliation in pyloric obstruction | Sara Carvalhal | Received |
84-P | Impact On Survival Of The Number Of Lymph Nodes Removed In Extended D-2 Lymphadenectomy For Gastric Cancer | Antonio Chiappa | Received |
85-P | Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with advanced gastric cancer | Satoru Iwasa | Received |
89-P | Transient elastography (FibroScan) predictor of hepatocellular carcinoma prognosis in patients referred to surgical treatment | Andra Iulia Suceveanu | Received |
91-P | Incidental Hepatocellular Carcinoma: A hidden foe for liver transplant recipients? | Renata Senkerikova | Received |
92-P | SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN NORTHERN GREECE. THE ROLE OF HBV INFECTION AND THE VALUE OF SORAFENIB IN INTERMEDIATE STAGE OF DISEASE. | Georgios Nalmpantidis | Received |
93-P | Treatment Outcomes of Patients with Extremely Advanced Inoperable Hepatocellular Carcinoma (HCC) after Yttrium-90 Radioembolization | Victor Lee | Received |
95-P | Efficacy of continued sorafenib treatment after radiological confirmation of disease progression in patients with advanced hepatocellular carcinoma | Yoshiyuki Wada | Received |
98-P | Health Related Quality of Life and Survival in Patients Diagnosed with Hepatocellular Carcinoma and Treated with Transarterial Chemoembolization or Yttrium-90 | Kathryn Bress | Received |
100-P | A retrospective study of liver stereotactic ablative radiotherapy: 21 months of follow-up | Samuel Palumbo | Received |
101-P | The role of Choi criteria in assessing response to tyrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC) | Fiona McCarthy | Received |
103-P | Comparison of Hepatic Resection and Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Meta-Analysis of 16,103 Patients | Qinghua Xu | Received |
105-P | Oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in first-line treatment of Asian patients with MET-positive advanced hepatocellular carcinoma and Child-Pugh class A liver function: Phase Ib/II, multicenter, randomized trial | Ann-Lii Cheng | Received |
106-P | The impact of FOLFIRINOX chemotherapy on the treatment pattern of patients with pancreas cancer seen at a tertiary referral centre in the UK. | Neha Chopra | Received |
109-P | Performance status remained the most important prognostic factor in pancreas cancer patients, single center experience | &304;brahim Trker | Received |
112-P | Evaluation of bowel doses in patients undergoing dose escalated post operative Intensity Modulated Radiotherapy in Perimapullary Cancers | AMIT BAHL | Received |
116-P | Standard clinical practice of FOLFIRINOX in Advanced/Metastatic Pancreatic Cancer (PC) Patients: A Canadian Registry | jean maroun | Received |
117-P | Gemcitabine(G)-Erlotinib(E) versus Gemcitabine-Erlotinib-Capecitabine(C) in the first line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from Spanish TTD Collaborative Group | Susana Rodríguez | Received |
118-P | FOLFIRINOX IN PANCREATIC CANCER: THE NATIONAL CANCER INSTITUTE OF MILAN SINGLE EXPERIENCE. | KATIA FIORELLA DOTTI | Received |
124-P | LYMPH NODE INVOLVEMENT IN STANDARD LYMPHADENECTOMY FOR RESECTABLE PANCREATIC HEAD ADENOCARCINOMA | Daniel Kostov | Received |
125-P | A retrospective study of the prognostic value of various pathological and immunohistochemical features in tissue samples from patients with pancreatic neuroendocrine neoplasms | Nizar BAWAHAB | Received |
127-P | Multimodality treatment approach for locally advanced pancreatic cancer | Alexander Siebenhuener | Received |
128-P | Prognostic significance of CEA, CA19-9 and CA72-4 serum level before and after preoperative chemotherapy of esophagogastric junction adenocarcinoma | Milada Zemanova | Received |
130-P | Serum albumin (SA) as a predictor of response to chemotherapy in patients with locally advanced (LA) esophageal cancer. | Erika Ruiz-Garcia | Received |
132-P | Is a complete remission of intestinal metaplasia a suitable endpoint in patients undergoing radiofrequency ablation (RFA)? Long-term results of RFA treatment in 67 consecutive patients | Jana Krajciova | Received |
135-P | Phase I trial of 5-FU, Docetaxel and Nedaplatin combination therapy for metastatic esophageal cancer | Shinichi Nishina | Received |
137-P | LOCAL ADVANCED ESOPHAGEAL CANCER: PRECISE PREDICTION OF 5-YEAR SURVIVAL AFTER COMBINED ESOPHAGOGASTRECTOMIES | Oleg Kshivets | Received |
141-P | Electroneurography in evaluation of peripheral neuropathy during oxaliplatin-based chemotherapy for colorectal cancer. | Aneta Zygulska | Received |
146-P | To select the therapies in gastric carcinoid tumors | Sei Kurokawa | Received |
148-P | Presentation of Insulinoma in developing world | Manish Kaushal | Received |
149-P | Anorectal malignant melanoma experience of a single portuguese institution | Isália Miguel | Received |
151-P | Gastric neuroendocrine tumors: a single center experience. | IOANNIS PILPILIDIS | Received |
158-P | Image-guided hypofractionated stereotactic ablative radiotherapy for the liver: the MAASTRO experience | Lien Van De Voorde | Received |
159-P | Diagnosis, staging and treatment of cholangiocarnioma; a retrospective analysis of our last decade of experience | Heppell Hebert Mathieu | Received |
160-P | GASTROINTESTINAL CANCERS: EPIDEMIOLOGICAL, CLINICAL, HISTOLOGICAL AND THERAPEUTIC CHARACTERISTIC (210 CASES TREATED IN THE RADIOTHERAPY DEPARTMENT OF UNIVERSITY HOSPITAL OF HASSAN II-FES-MOROCCO BETWEEN JANUARY 2012 AND DECEMBER 2013) | fatima zahra farhane | Received |
161-P | The provision of a pre-operative immunomodulating diet in patients undergoing radical resection for upper gastrointestinal cancers does not reduce the risk of post-operative chest infection | Petra Goldsmith | Received |
167-P | INTERNATIONAL SCIENTIFIC COMMUNICATIONS IN THE FIELD OF RECTAL CANCER PATIENTS QUALITY OF LIFE | Daniel Kostov | Received |
168-P | INTERNATIONAL VISIBILITY OF RESEARCH ON INTERSPHINCTERIC RESECTIONS FOR RECTAL CANCER | Daniel Kostov | Received |
169-P | Neoadjuvant chemoradiation for rectal cancers | Charu Singh | Received |
170-P | EPIDEMIOLOGY OF RECTAL CANCER IN THE REGIONS OF VARNA AND DOBRICH, BULGARIA | Daniel Kostov | Received |
171-P | Incidence of Kirsten-Ras Gene Mutation and Its Association with Clinical and Pathological Factors in Colorectal Carcinoma: single institute retrospective experience | Vinayak Maka | Received |
174-P | Association between colorectal cancer survival outcomes and GWAS-identified colorectal cancer susceptibility polymorphism in Korean population | Byung Woog Kang | Received |
175-P | Simultaneous detection of KRAS, NRAS and BRAF hotspot mutations on Ion Torrent PGM platform. | celine de rop | Received |
176-P | The levels of methionine determined by amino acid profiling correlate with the degree of methylation in colon cancer tissues. | Yuji Takayama | Received |
177-P | KRAS Mutation Status in Colombian patients with colorectal cancer: Analysis of 844 consecutive cases | Rocío del Pilar López Panqueva | Received |
179-P | Intronic SMAD7 gene polymorphisms, rs12953717 and rs4464148, in association with risk of Colorectal Cancer | Shaghayegh Derakhshani | Received |
180-P | BEVACIZUMAB IN COMBINATION WITH IRINOTECAN AND CAPECITABINE AS FIRST-LINE TREATMENT FOR mCRC EFFICACY AND SAFETY | SAA JUNGI&262; | Received |
181-P | Detention of molecular changes between primary tumor (PT) and synchronous resected liver metastases (srLm) in colo-rectal cancer (CRC) patients after first line cetuximab based chemotherapy (CT). | DANIELA ADUA | Received |
184-P | Selective, synergic and additive interaction types between 5-fluorouracil and 2-oxohexyl isothiocyanate after sequential treatment in colon cancer cell lines | Ma&322;gorzata Milczarek | Received |
185-P | Combined administration of 5-fluorouracil as well as 2-oxohexyl isothiocyanate with selol give synergistic toxic effect on HT -29 colorectal cancer cell lines. | Lidia Sliwka | Received |
187-P | Incidence of Hepatic Resection among Colorectal Cancer Patients with Liver Metastases | Keith Betts | Received |
188-P | Isothiocyanates are chemopreventive compounds and reduce the MDR phenomenon - study on normal and colon cancer cells | Katarzyna Lubelska | Received |
191-P | Is there a trend toward lower participation in colorectal cancer screening among certain populations? | Olivier Galut | Received |
192-P | ABDOMINAL OBESITY IS ASSOCIATED WITH THE NUMBER OF COLORECTAL POLYPS IN MEN BUT NOT IN WOMEN | Miros&322;aw Jarosz | Received |
194-P | KRAS genotype and the prevalent c.35 G A mutation affect significantly worse prognosis of metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab. | Gemma Bruera | Received |
195-P | Clinical validation of a novel multiplex kit for all RAS mutations in colorectal cancer: Results of RASKET (RAS KEy Testing) prospective multicenter study | Toshihiro Kudo | Received |
196-P | Expression of aquaporin-1, aquaporin-3, and aquaporin-5 with nodal metastasis in colon cancer | Byung Woog Kang | Received |
197-P | Comparison of a new multiplexed multigene approach with pyrosequencing in diagnostic molecular biology of colorectal cancer (CRC) | Giovanna De Maglio | Received |
198-P | KRAS mutations in colorectal cancer patients in Serbia: 5 years experience of central testing | Radmila Jankovic | Received |
199-P | Analysis of Molecular Alterations for Predicting Clinical Benefit to Cetuximab plus Chemotherapy in first-line Metastatic Colorectal Cancer (mCRC) | Javier Sastre | Received |
202-P | Cyclooxygenase-2 (COX-2) expression in a cohort of Greek patients with colorectal cancer (CRC) | DIMITRIOS TZILVES | Received |
203-P | Value of monitoring CEA in patients with colon cancer receiving adjuvant chemotherapy | Andrea Nagy | Received |
205-P | Cytokines, depression and anxiety in colorectal cancer patients in different stages of the antitumor therapy | Dr. Miranda | Received |
206-P | Hyperuricemia at time of diagnosis is a poor prognostic factor for patients with colorectal cancer: a pilot study | Ozgur Tanriverdi | Received |
209-P | Tolerability and Safety of cytotoxic chemotherapy in patients over 80 with colorectal cancer (CRC) at Heart of England NHS Foundation Trust (HEFT) | Racha Kussaibati | Received |
210-P | Under prescription of targeted therapy in first-line metastatic colorectal cancer in elderly people: a cohort study in a French center. | Amaury daste | Received |
211-P | Prespecified subgroup analyses in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer | HIROSHI TAMAGAWA | Received |
213-P | COLORECTAL CANCER IN PATIENTS AGE 40 AND UNDER: A RETROSPECTIVE ANALYSIS OF DATABASE FROM THE INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA | Jelena Spasic | Received |
214-P | Use of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer (mCRC): a post-hoc analysis of the GLUTOX study | Francois Leblond | Received |
215-P | Efficacy, safety and patient-reported outcomes of oxaliplatin-based chemotherapy in elderly patients with colorectal cancer (CRC): a post-hoc analysis of the GLUTOX study | Francois Leblond | Received |
216-P | Evaluating the learning curve of Magnetic Resonance Imaging (MRI) as a predictive tool in locally advanced rectal cancer (RC) - a retrospective 12-year experience. | CHA LEN LEE | Received |
220-P | The sequential administration of XELOX and XELIRI was effective, feasible and manageable for patients with mCRC. | Taro Fukui | Received |
223-P | Survival advantage of metformin in patients with colorectal cancer and type II diabetes mellitus: The Middle Eastern perspective. | Ali Shamseddine | Received |
230-P | Salvage chemotherapy in metastatic colorectal cancer with combination of capecitabine and mitomycin C. | Aneta Zygulska | Received |
231-P | Efficacy and safety of bevacizumabhepatic arterial infusion chemotherapy of FOLFIRI for unresectable colorectal liver metastases | Yoshiyuki Wada | Received |
232-P | Extending targeted therapy beyond first-line (1L) chemotherapy backbone: real-world treatment patterns and outcomes in patients with metastatic colorectal cancer (mCRC) | Manasee Shah | Received |
233-P | Assessment of morphological response contributes to selection of candidates for rescue liver resection among patients undergoing chemotherapy for initially unresectable colorectal liver metastasis | Koichi Suzuki | Received |
234-P | Analysis of Glasgow Prognostic Score(GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901 | SATOSHI YUKI | Received |
236-P | The PRIME study: Survival outcomes for patients with RAS/BRAF wild-type metastatic colorectal cancer, by baseline ECOG performance status | Marc Peeters | Received |
237-P | Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in the UK | Karin Sennfalt | Received |
238-P | Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in Italy | Karin Sennfalt | Received |
244-P | Single institution results of first- line treatment with bevacizumab plus chemotherapy in metastatic colorectal cancer (mCRC) | Jaroslava Barkmanova | Received |
246-P | Management of patients with colorectal liver metastasis harboring more than 5 multiple tumors | Kosuke Ichida | Received |
248-P | Cetuximab with irinotecan or oxaliplatin for 1st-line metastatic colorectal cancer: updated data of effectiveness in the EREBUS cohort compared to pivotal trials | Denis Smith | Received |
249-P | Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, single-center study comparing chemotherapy alone or in combination with cetuximab or bevacizumab. | Vincenzo Dadduzio | Received |
250-P | Bevacizumab in combination with neoadjuvant therapy in elderly patients with liver metastases of colorectal cancer-Single center experience | marija ristic | Received |
251-P | Bevacizumab in the first line therapy of metastatic colorectal cancer in older patients, study AVEX in clinical practice. | Lenka Ost&345;íková | Received |
252-P | Cost-effectiveness of different chemotherapy strategies for patients with advanced colorectal cancer in Brazil: a Public Health System perspective | Andre Sasse | Received |
259-P | Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in North Japan multicenter phase II study (NORTH/HGCSG1003) | Norihiko Takahashi | Received |
261-P | The management of peritoneal surface malignancies at the American University of Beirut Medical Center: initial experience | Faek Jamali | Received |
266-P | Adjuvant regorafenib in stage IV colorectal cancer (CRC) after curative treatment of liver metastases: A phase III randomized, placebo-controlled study (COAST) | Eric Van Cutsem | Received |
267-P | Dose-dense temozolomide (TMZ) in patients with advanced chemorefractory colorectal cancer (CRC) and MGMT promoter methylation | Filippo Pietrantonio | Received |
269-P | The CAIRO4 study: The role of surgery of the primary tumor with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer: a randomized phase III study. | Jorine t Lam - Boer | Received |
272-P | Neoadjuvant Chemotherapy capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer | Takeshi Kato | Received |
275-P | Clinical significance of tumour regression grade in locally-advanced rectal cancer treated with preoperative chemoradiotherapy | ALBA HERNANDEZ | Received |
279-P | Ordinary rectal adenocarcinoma vs. primary rectal signet-ring cell carcinoma | LOUKILI KAOUTAR | Received |
10008-O | Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone, as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: the POSEIDON Phase I/randomized Phase II trial | Elena Elez | Received |
10243-P | Deep responders represent a group with excellent survival in patients with metastatic colorectal cancer(mCRC) treated with Triplet chemotherapy regimens(TCR) | Shouki Bazarbashi | Received |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||